Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Complete Title: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE® STATUS
Trial Phase: I/II
Investigator: Petros Grivas
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon`s OncoSignature® test status.
Keywords:
- Endometrial Cancer
- Ovarian Cancer
- Urothelial Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I/II
Petros Grivas
RG1123312
NCT05548296
A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE® STATUS
Endometrial Cancer
Ovarian Cancer
Urothelial Cancer